Because BCCIP deficiency would impair homologous recombination (HR) and hinder cell proliferation, it was unknown how some of the benign nodules (although a relatively rare event at a frequency of 3/32) evolved into malignant tumor while BCCIP remained downregulated (Fig. 4e). Here, BCCIP is linked to cancer.